Crinetics Pharmaceuticals (CRNX) Receivables (2024 - 2026)

Crinetics Pharmaceuticals' Receivables history runs 3 years deep, the most recent figure standing at $14.6 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $14.6 million (changed N/A YoY), while the FY2025 annual figure was $8.4 million, changed 0.48% from the prior year.
• Receivables was $14.6 million for Q1 2026 at Crinetics Pharmaceuticals, up from $8.4 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $14.6 million in Q1 2026 to a low of $8.3 million in Q4 2024.
• Historically, Receivables has averaged $10.4 million across 3 years, with a median of $8.4 million in 2025.
• Biggest YoY gain for Receivables was 0.48% in 2025; the steepest drop was 0.48% in 2025.
• A 3-year view of Receivables shows it stood at $8.3 million in 2024, then increased by 0.48% to $8.4 million in 2025, then jumped by 75.33% to $14.6 million in 2026.
• The last three Receivables figures came in at $14.6 million (Q1 2026), $8.4 million (Q4 2025), and $8.3 million (Q4 2024), per Business Quant data.